Since this is a relatively new scheme (less than 3 years), we do not have sufficient data to conduct meaningful performance analysis
Expense ratio of the scheme (1.51%) is roughly in line with average expense ratio of the category (1.66%), excluding index funds and ETFs
This measures the relative expense of the scheme with respect to average expense ratio of the category. Investors should always prefer schemes with lower expense, everything else remaining the same
What is Expense ratio?
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
